Breaking Down WuXi AppTec Co., Ltd. Financial Health: Key Insights for Investors

Peeling back the numbers on WuXi AppTec Co., Ltd. (2359.HK) reveals a company with robust top-line momentum-reported revenue of RMB39,241 million in 2024 (up 5.2% YoY ex-COVID project), Q4 2024 revenue of RMB11,539 million (+6.9% YoY) and H1 2025 revenue of RMB20,799.3 million (+20.6% YoY; continuing operations RMB20,409.3 million, +24.2%)-supported by a swelling backlog of RMB56.69 billion as of June 30, 2025 (+37.2% YoY) and a 2025 revenue target of RMB41.5-43.0 billion; profitability paints a mixed picture with 2024 net profit attributable to owners at RMB9,352.6 million (down 12.5% YoY) while adjusted non‑IFRS margins hit a record 27.0% in 2024 and adjusted non‑IFRS net profit rose to RMB6,314.8 million in H1 2025 (+44.4%, margin 30.4%); the balance sheet shows total debt of CN¥8.6 billion against equity of CN¥71.5 billion (debt/equity 12%), cash and short‑term investments of CN¥33.7 billion, total assets CN¥94.6 billion and liabilities CN¥23.1 billion, yet an interest coverage ratio of -3.2 and EBIT of CN¥15.2 billion flag financing strain amid recent capital raises (US$500m convertible bond Oct 2024 and ~US$980.98m share placement announced July 2025) that have in turn pressured the share price (shares fell >13% after Oct 2024 bond news and 6.9% after the July 2025 placement) even as the market values the company at HK$339.54 billion with a stock price of HK$112.70 (one‑year average target HK$137.77, P/E 20.26, dividend yield 1.28%); dive into the full article for a detailed breakdown of revenue drivers, profitability shifts, liquidity dynamics, valuation metrics and the key risks and growth levers investors need to weigh

WuXi AppTec Co., Ltd. (2359.HK) - Revenue Analysis

WuXi AppTec reported steady topline expansion in recent periods, driven by recovery in R&D outsourcing demand and backlog growth. Key reported figures and management guidance provide a view into near-term revenue trajectory and operational momentum.

• 2024 full-year revenue: RMB 39,241 million (reported), representing a 5.2% year-over-year increase on a pro forma basis excluding the COVID-19 commercial project in 2023.
• Q4 2024 revenue: RMB 11,539 million, up 6.9% year-over-year.
• H1 2025 revenue: RMB 20,799.3 million, up 20.6% year-over-year.
• H1 2025 revenue from continuing operations: RMB 20,409.3 million, up 24.2% year-over-year.
• Backlog for continuing operations (as of June 30, 2025): RMB 56.69 billion, a 37.2% increase versus prior year.
• 2025 management revenue target: growth of 10-15%, implying total revenue of RMB 41.5-43.0 billion.

Implications for investors include improved organic demand (reflected in H1 2025 growth and backlog expansion) and a management outlook that implies moderate continued growth. For additional investor context and shareholder composition, see Exploring WuXi AppTec Co., Ltd. Investor Profile: Who's Buying and Why?

WuXi AppTec Co., Ltd. (2359.HK) - Profitability Metrics

Key profitability outcomes show mixed annual results for 2024 but a strong operational rebound in H1 2025, driven by margin expansion in adjusted non-IFRS measures.

• 2024 reported net profit attributable to owners: RMB 9,352.6 million (down 12.5% vs. 2023).
• 2024 adjusted non‑IFRS net profit: RMB 10,582.5 million (down 2.5% vs. 2023) with a record adjusted non‑IFRS net profit margin of 27.0%.
• H1 2025 reported net profit attributable to owners: RMB 8,287.3 million (up 95.5% YoY).
• H1 2025 adjusted non‑IFRS net profit: RMB 6,314.8 million (up 44.4% YoY) and adjusted margin 30.4% (vs. 25.4% in H1 2024).

• Margin-driven improvement: despite a slight decline in annual adjusted profit, 2024's 27.0% adjusted margin and the further jump to 30.4% in H1 2025 indicate stronger cost control and higher-quality revenue mix.
• Seasonality and momentum: the near-doubling of H1 2025 reported net profit vs. H1 2024 highlights pronounced recovery or one-off gains concentrated in the first half - investors should assess sustainability.
• Reconciliation view: the divergence between reported and adjusted non‑IFRS profits suggests one-off items or accounting impacts in 2024; adjusted metrics better reflect operating performance.

For more on shareholder composition and investor activity related to these profitability shifts, see: Exploring WuXi AppTec Co., Ltd. Investor Profile: Who's Buying and Why?

WuXi AppTec Co., Ltd. (2359.HK) Debt vs. Equity Structure

• Total debt (as of June 30, 2025): CN¥8.6 billion
• Total equity (as of June 30, 2025): CN¥71.5 billion
• Debt-to-equity ratio: 12%
• Total assets: CN¥94.6 billion
• Total liabilities: CN¥23.1 billion
• Cash and short-term investments: CN¥33.7 billion
• EBIT: CN¥15.2 billion
• Interest coverage ratio: -3.2
• October 2024: $500 million convertible bond raised (for global expansion and debt refinancing)
• July 2025: planned share placement to raise ~ $980.98 million (to support global expansion)

• Low debt-to-equity (12%) signals conservative leverage relative to equity base.
• Large cash buffer (CN¥33.7B) provides liquidity for operations and near-term financing needs.
• Negative interest coverage (-3.2) suggests interest expense exceeds EBIT - a watch item despite healthy cash and equity.
• Recent capital raises (Oct 2024 convertible bond and Jul 2025 share placement) indicate active balance-sheet management to fund global expansion and refinance obligations.

WuXi AppTec Co., Ltd. (2359.HK) - Liquidity and Solvency

Key balance-sheet and cash-flow metrics for assessing liquidity and solvency show a robust short- and long-term asset base, strong recent cash generation, but a negative interest coverage that warrants attention.

• Short-term assets: CN¥53.8 billion
• Short-term liabilities: CN¥19.4 billion
• Long-term assets: CN¥53.8 billion
• Long-term liabilities: CN¥3.7 billion
• Cash and short-term investments (Jun 30, 2025): CN¥33.7 billion
• Operating cash flow (H1 2025): RMB7.07 billion (+49.1% YoY)
• Free cash flow (2024): RMB7.98 billion (record high)
• Interest coverage ratio: -3.2 (interest expense > operating income)

Implications for investors:

• The excess of short-term assets (CN¥53.8B) over short-term liabilities (CN¥19.4B) implies comfortable near-term liquidity and a healthy current ratio buffer.
• Substantial cash and short-term investments (CN¥33.7B) provide immediate liquidity and support operational flexibility.
• Strong cash generation momentum - H1 2025 operating cash flow of RMB7.07B (+49.1% YoY) and record FCF of RMB7.98B in 2024 - reduces reliance on external financing for growth or capex.
• The negative interest coverage ratio (-3.2) signals that interest expenses exceed operating income and highlights potential stress from financing costs; monitoring interest-bearing debt and earnings recovery is critical.

Further reading: Exploring WuXi AppTec Co., Ltd. Investor Profile: Who's Buying and Why?

WuXi AppTec Co., Ltd. (2359.HK) - Valuation Analysis

Analyst sentiment moved higher in late 2025: the average one‑year price target was revised up to HK$137.77 in November 2025 - an 11.49% increase from the prior HK$123.56 estimate - indicating upward revisions to expectations.

• Valuation level: P/E of 20.26 situates WuXi AppTec in a premium segment versus many CRO/CDMO peers, reflecting expected earnings growth and scale advantages.
• Income component: 1.28% dividend yield is modest; total return thesis relies mainly on earnings expansion and multiple re‑rating.
• Analyst dispersion: target range HK$107.71-HK$161.64 signals heterogeneity in margin and backlog forecasting assumptions.

For deeper context on business model, ownership and how revenue streams drive these valuation metrics, see: WuXi AppTec Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money

WuXi AppTec Co., Ltd. (2359.HK) - Risk Factors

• Market reaction to financing events: In October 2024 shares fell over 13% after announcement of a US$500 million convertible bond offering.
• Geopolitical / regulatory risk: The U.S. House passage of the Biosecure Act in September 2024 targets restrictions on federal contracts with firms like WuXi AppTec on national security grounds, potentially reducing U.S. revenue or contract access.
• Equity dilution and investor sentiment: In July 2025 the company announced a share placement expected to raise approximately CN¥7.0 billion (≈US$980.98 million), triggering a 6.9% stock price drop.
• Interest burden and coverage: An interest coverage ratio of -3.2 indicates interest expense exceeds operating income, signifying negative operating income relative to interest obligations.
• Profitability vs. financing cost: Reported EBIT of CN¥15.2 billion combined with the negative interest coverage highlights potential difficulty in meeting interest expense from operating earnings.
• Capital structure: A debt-to-equity ratio of 12% suggests leverage is moderate in absolute terms but, given coverage weakness, still a material risk to solvency and flexibility.

• Operational concentration: Exposure to cross-border R&D and manufacturing contracts increases sensitivity to trade restrictions and biosafety legislation.
• Financing flexibility: Recent capital raises (convertible bond, share placement) suggest reliance on external financing; further market access constraints could raise cost of capital.
• Investor dilution risk: Large equity raises dilute existing shareholders and can pressure share liquidity and valuation.

WuXi AppTec Co., Ltd. (2359.HK) Growth Opportunities

• Backlog strength: continuing-operations backlog of RMB56.69 billion as of June 30, 2025 (up 37.2% YoY).
• Revenue guidance: 2025 revenue target of +10-15%, implying RMB41.5-43.0 billion.
• Capital raise: planned ~US$980.98 million (July 2025 share placement) to support global expansion initiatives.
• Operational focus: capacity expansion, capability enhancement, production optimization, and efficiency improvements to support long-term growth.

• Implications of backlog and guidance: A large, growing backlog provides revenue visibility that supports the 10-15% growth target, but conversion timing, mix (CRO/CDMO vs. other services), and margin dynamics will determine realized top- and bottom-line results.
• Use of proceeds from placement: The ~US$981M raise is earmarked to accelerate global expansion and capacity buildout-critical to meeting demand from the expanded backlog but dilutive in the near term.
• Financial risk: An interest coverage ratio of -3.2 alongside EBIT of CN¥15.2 billion signals that interest expenses exceed operating income, highlighting potential stress in servicing debt and the importance of margin improvement and cash generation.